Skip to main content
. Author manuscript; available in PMC: 2014 Feb 20.
Published in final edited form as: Bioconjug Chem. 2013 Jan 10;24(2):167–175. doi: 10.1021/bc300355y

Figure 1.

Figure 1

Specific and M225 dose-dependent binding of M225-PEG-NP to EGFR+ cells. M225-PEG-NP nanoparticles show significantly greater binding to A431 (EGFR+) cells compared to untreated controls, A431 cells treated with PEGylated beads, and M225-preblocked A431 cells treated with M225-PEG-NP nanoparticles *(p < 0.05) thus demonstrating binding specificity of nanoparticles for EGFR. Nanoparticle binding to A431 cells was directly proportional to the number of surface-conjugated M225 antibodies. PEGylated beads and M225-PEG-NP nanoparticles showed no significant binding in H520 (EGFR-) cells (p > 0.05).